Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares OutstandingShort-Term Debt repayments
Ratios

BioNexus Gene Lab (BGLC) Long-Term Debt Issuances (2019 - 2025)

Historic Long-Term Debt Issuances for BioNexus Gene Lab (BGLC) over the last 5 years, with Q1 2025 value amounting to $15528.0.

  • BioNexus Gene Lab's Long-Term Debt Issuances fell 2406.1% to $15528.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $29979.0, marking a year-over-year increase of 29162.64%. This contributed to the annual value of $78835.0 for FY2024, which is 9441.53% down from last year.
  • Latest data reveals that BioNexus Gene Lab reported Long-Term Debt Issuances of $15528.0 as of Q1 2025, which was down 2406.1% from $20448.0 recorded in Q1 2024.
  • In the past 5 years, BioNexus Gene Lab's Long-Term Debt Issuances registered a high of $20448.0 during Q1 2024, and its lowest value of -$8550.0 during Q1 2021.
  • Over the past 3 years, BioNexus Gene Lab's median Long-Term Debt Issuances value was -$5997.0 (recorded in 2021), while the average stood at $2926.6.
  • As far as peak fluctuations go, BioNexus Gene Lab's Long-Term Debt Issuances plummeted by 41898.94% in 2021, and later crashed by 2406.1% in 2025.
  • Quarter analysis of 3 years shows BioNexus Gene Lab's Long-Term Debt Issuances stood at -$5997.0 in 2021, then surged by 440.97% to $20448.0 in 2024, then dropped by 24.06% to $15528.0 in 2025.
  • Its Long-Term Debt Issuances stands at $15528.0 for Q1 2025, versus $20448.0 for Q1 2024 and -$5997.0 for Q3 2021.